1. Home
  2. DQ vs NUVB Comparison

DQ vs NUVB Comparison

Compare DQ & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DAQO New Energy Corp.

DQ

DAQO New Energy Corp.

HOLD

Current Price

$20.85

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.47

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DQ
NUVB
Founded
2006
2018
Country
China
United States
Employees
N/A
291
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
DQ
NUVB
Price
$20.85
$4.47
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$28.91
$11.38
AVG Volume (30 Days)
595.1K
3.8M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$70.27
$190.15
Revenue Next Year
$34.95
$62.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.41
$1.57
52 Week High
$36.59
$9.75

Technical Indicators

Market Signals
Indicator
DQ
NUVB
Relative Strength Index (RSI) 38.21 44.93
Support Level $20.47 $4.07
Resistance Level $25.90 $5.55
Average True Range (ATR) 0.91 0.21
MACD 0.02 0.07
Stochastic Oscillator 16.80 71.79

Price Performance

Historical Comparison
DQ
NUVB

About DQ DAQO New Energy Corp.

Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: